Tvardi Therapeutics (TVRD) grants 6,000 stock options to director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tvardi Therapeutics, Inc. director Susan Shiff, Ph.D. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036. 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, subject to her continuous service. Following this grant, she holds 6,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shiff Susan Ph.D.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 6,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 6,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 6,000 options
Exercise price: $2.78 per share
Underlying shares: 6,000 shares
+3 more
6 metrics
Stock options granted
6,000 options
Grant to director Susan Shiff, Ph.D.
Exercise price
$2.78 per share
Strike price for granted stock options
Underlying shares
6,000 shares
Common stock underlying granted options
Vesting date trigger
June 9, 2027
Earlier of this date or next annual meeting
Option expiration
June 8, 2036
Expiration date of stock options
Post-grant derivative holdings
6,000 options
Total stock options held after transaction
Key Terms
Stock Option (right to buy), grant/award acquisition, Common Stock, annual meeting of stockholders
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
annual meeting of stockholders financial
"the date of the Issuer's next annual meeting of stockholders"
FAQ
What did Tvardi Therapeutics (TVRD) disclose in this Form 4 for Susan Shiff?
Tvardi Therapeutics reported a stock option grant to director Susan Shiff, Ph.D. for 6,000 shares of common stock. The award is part of her director compensation and does not reflect an open-market purchase or sale of shares.
How many Tvardi Therapeutics (TVRD) options were granted to Susan Shiff and at what price?
Susan Shiff received 6,000 stock options covering Tvardi common shares with an exercise price of $2.78 per share. This means she can buy up to 6,000 shares at $2.78 if the options vest and she chooses to exercise them.
When do Susan Shiff’s Tvardi Therapeutics (TVRD) stock options vest?
All of Susan Shiff’s 6,000 stock options vest 100% on the earlier of June 9, 2027 or Tvardi’s next annual meeting of stockholders. Vesting is conditioned on her maintaining continuous service with the company through the applicable vesting date.
What is the expiration date of Susan Shiff’s Tvardi Therapeutics (TVRD) stock options?
The granted stock options expire on June 8, 2036. After that date, any unexercised portion of the 6,000 options will lapse. Until expiration, she may exercise vested options at the fixed exercise price of $2.78 per share.
Is Susan Shiff’s Tvardi Therapeutics (TVRD) Form 4 transaction a market purchase or sale?
This Form 4 reports a grant/award acquisition of stock options, not an open-market trade. Tvardi granted her 6,000 options at a $2.78 exercise price as compensation, and no shares were bought or sold on the public market in this transaction.
How many Tvardi Therapeutics (TVRD) derivatives does Susan Shiff hold after this grant?
Following this grant, Susan Shiff directly holds 6,000 stock options relating to Tvardi common stock. These options vest on the specified schedule and are exercisable at $2.78 per share until their expiration on June 8, 2036, assuming continued service.